Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways
Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence...
Guardado en:
Autores principales: | Michelle M. Williams, Sabrina A. Hafeez, Jessica L. Christenson, Kathleen I. O’Neill, Nia G. Hammond, Jennifer K. Richer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e2edb5704120464694919c5e63ee7665 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Epithelial-to-Mesenchymal Plasticity in Circulating Tumor Cell Lines Sequentially Derived from a Patient with Colorectal Cancer
por: Pelin Balcik-Ercin, et al.
Publicado: (2021) -
GJA1 promotes hepatocellular carcinoma progression by mediating TGF-β-induced activation and the epithelial–mesenchymal transition of hepatic stellate cells
por: Niu Gengming, et al.
Publicado: (2021) -
Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial–mesenchymal transition inhibition
por: Li W, et al.
Publicado: (2017) -
Crotoxin Modulates Events Involved in Epithelial–Mesenchymal Transition in 3D Spheroid Model
por: Ellen Emi Kato, et al.
Publicado: (2021) -
Tumor suppressive function of Matrin 3 in the basal-like breast cancer
por: Yang,Jaehyuk, et al.
Publicado: (2020)